Evidence map›Paper›PMID 35191177›Full record

ArticleJournal of cellular and molecular medicine2022

Curcumin analog HO-3867 triggers apoptotic pathways through activating JNK1/2 signalling in human oral squamous cell carcinoma cells.

Chi-Wei Chen, Ming-Ju Hsieh, Po-Chung Ju, Yi-Hsien Hsieh, Chun-Wen Su, Yen-Lin Chen, Shun-Fa Yang, Chiao-Wen Lin

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Curcumin inhibits the proliferation and migration of osteosarcoma by regulating the expression of superZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. BRCA2 Status Alters the Effect of the P53 Reactivator HO-3867 in Ovarian Cancer Cells.Journal of cancer science and clinical therapeutics · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Chi-Wei ChenDepartment of Life Science, College of Science and Engineering, National Dong Hwa University, Hualien, Taiwan.
Ming-Ju HsiehOral Cancer Research Center, Changhua Christian Hospital, Changhua, Taiwan.
Po-Chung JuSchool of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Yi-Hsien HsiehInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.ORCID 0000-0003-4942-1888
Chun-Wen SuInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Yen-Lin ChenInstitute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan.
Shun-Fa YangInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.ORCID 0000-0002-0365-7927
Chiao-Wen LinInstitute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan.
Chung Shan Medical University Hospital · TWNational Chung Hsing University · TWNational Dong Hwa University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human oral squamous cell carcinoma (OSCC) is the common head and neck malignancy in the world. While surgery, radiotherapy and chemotherapy are emerging as the standard treatment for OSCC patients, the outcome is limited to the recurrence and side effects. Therefore, patients with OSCC require alternative strategies for treatment. In this study, we aimed to explore the therapeutic effect and the mode of action of the novel curcumin analog, HO-3867, against human OSCC cells. We analysed the cytotoxicity of HO-3867 using MTT assay. In vitro mechanic studies were performed to determine whether MAPK pathway is involved in HO-3867 induced cell apoptosis. As the results, we found HO-3867 suppressed OSCC cells growth effectively. The flow cytometry data indicate that HO-3867 induce the sub-G1 phase. Moreover, we found that HO-3867 induced cell apoptosis by triggering formation of activated caspase 3, caspase 8, caspase 9 and PARP. After dissecting MAPK pathway, we found HO-3867 induced cell apoptosis via the c-Jun N-terminal kinase (JNK)1/2 pathway. Our results suggest that HO-3867 is an effective anticancer agent as its induction of cell apoptosis through JNK1/2 pathway in human oral cancer cells.

Indexed as

Carcinoma, Squamous CellCurcuminHead and Neck NeoplasmsMouth NeoplasmsApoptosisCell Line, TumorCell ProliferationHumansPiperidonesSquamous Cell Carcinoma of Head and Neck(3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one)CurcuminPiperidonesapoptosisHO-3867JNK1/2oral squamous cell carcinoma

Identifiers

PMID35191177
PMCPMC8995445
OpenAlexW4213287294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.